PCP
KYMR icon

Perbak Capital Partners’s Kymera Therapeutics KYMR Stock Holding History

Perbak Capital Partners’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-6,443
Closed -$537K – 137
2026
Q1 		$537K Buy
6,443
+3,805
+144% +$301K 0.13% 179
2025
Q4 		$205K Sell
2,638
-4,866
-65% -$329K 0.06% 217
2025
Q3 		$425K Buy
+7,504
New +$338K 0.07% 243

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Perbak Capital Partners's KYMR Position: Q2 2026 in Review

Perbak Capital Partners sold out of Kymera Therapeutics (KYMR) in Q2 2026, closing a stake of 6,443 shares — an estimated $537K sold.

Perbak Capital Partners first reported a position in KYMR in Q3 2025 and held it in 3 quarters. The position peaked at $537K in Q1 2026. 277 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Perbak Capital Partners reported no remaining Kymera Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Perbak Capital Partners sold 6,443 Kymera Therapeutics shares in Q2 2026, an estimated $537K.
  • Perbak Capital Partners first reported a position in Kymera Therapeutics in Q3 2025 and held it in 3 quarters.
  • Perbak Capital Partners's Kymera Therapeutics position peaked at $537K in Q1 2026.
  • 277 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Perbak Capital Partners's 13F filing for Q2 2026.